Administration of human recombinant bone morphogenetic protein-2 for spine fusion may be associated with transient postoperative renal insufficiency

Spine

Volumn 35, Issue 7, 2010, Pages

  Latzman, Jonathan M ^a   Kong, Li ^a   Liu, Chuanju ^a   Samadani, Uzma ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b New York Harbor Health Care System Manhattan Veteran's Administration   (United States)

Author keywords

Adverse reaction; Renal insufficiency; Retrospective; Spinal fusion

Indexed keywords

INFUSE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG;

ARTICLE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEVER; HEART ARRHYTHMIA; HUMAN; KIDNEY FAILURE; MENTAL DISEASE; NEOPLASM; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SPINE FUSION; SUPRAVENTRICULAR TACHYCARDIA; SURGICAL TECHNIQUE; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

BONE MORPHOGENETIC PROTEINS; BONE SUBSTITUTES; FEMALE; HUMANS; LUMBAR VERTEBRAE; MALE; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SPINAL FUSION; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 77951667575     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181c71447     Document Type: Article

References (23)

1. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-899
2. Sampath TK, Muthukumaran N, Reddi AH. Isolation of osteogenin, an extracellular matrix-associated, bone-inductive protein, by heparin affinity chromatography. Proc Natl Acad Sci USA 1987;84:7109-7113
3. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988;242:1528-1534
4. Ye L, Lewis-Russell JM, Kyanaston HG, et al. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 2007; 22:1129-1147
5. Hamilton DK, Jones-Quaidoo SM, Sansur C, et al. Outcomes of bone morphogenetic protein-2 in mature adults: posterolateral non-instrumentassisted lumbar decompression and fusion. Surg Neurol 2008;69:457-461
6. Luhmann SJ, Bridwell KH, Cheng I, et al. Use of bone morphogenetic protein- 2 for adult spinal deformity. Spine (Phila Pa 1976) 2005;30(suppl): S110-7.
7. Herford AS, Boyne PJ. Reconstruction of Mandibular Continuity Defects With Bone Morphogenetic Protein-2 (rhBMP-2). J Oral Maxillofac Surg 2008;66:616-624
8. Dickinson BP, Ashley RK, Wasson KL, et al. Reduced morbidity and improved healing with bone morphogenic protein-2 in older patients with alveolar cleft defects. Plastic Reconstr Surg 2008;121:209-217
9. Jones NF, Brown EE, Vogelin E, et al. Bone morphogenetic protein as an adjuvant in the treatment of Kienbock's disease by vascular pedicle implantation. J Hand Surg Eur Vol 2008;33:317-321
10. Moshel YA, Hernandez EI, Kong L, et al. Acute renal insufficiency, supraventricular tachycardia and confusion after recombinant human bone morphogenetic protein two for lumbosacral spine fusion. J Neurosurg 2008;8:589-593
11. Glassman SD, Carreon L, Djurasovic M, et al. Posterolateral lumbar spine fusion with INFUSE bone graft. Spine J 2007;7:44-49
12. Mummaneni PV, Pan J, Haid RW, et al. Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves. J Neurosurg 2004;1:19-23.
13. Glassman SD, Dimar JR III, Burkus K, et al. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers. Spine 2007;32:1693-1698
14. Slosar PJ, Josey R, Reynolds J. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes. Spine J 2007;7:301-307
15. Burkus JK, Dorchak JD, Sanders DL. Radiographic assessment of interbody fusion using recombinant human bone morphogenetic protein type 2. Spine (Phila Pa 1976) 2003;28:372-377
16. Haid RW Jr, Branch CL Jr, Alexander JT, et al. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J 2004;4:527-38; discussion 538-539
17. Vaidya R, Sethi A, Bartol S, et al. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions. J Spinal Disord Tech 2008;21:557-562
18. Meisel HJ, Schnoring M, Hohaus C, et al. Posterior lumbar interbody fusion using rhBMP-2. Eur Spine J 2008;17:1735-1744
19. Mulconrey DS, Bridwell KH, Flynn J, et al. Bone morphogenetic protein (RhBMP-2) as a substitute for iliac crest bone graft in multilevel adult spinal deformity surgery: minimum two-year evaluation of fusion. Spine 2008;33: 2153-2159
20. Beck SE, Carethers JM. BMP suppresses PTEN expression via. RAS/ERK signaling. Cancer Biol Ther 2007;6:1313-1317
21. Beck SE, Jung BH, Del Rosario E, et al. BMP-induced growth suppression in colon cancer cells is mediated by p21WAF1 stabilization and modulated by RAS/ERK. Cell Signal 2007;19:1465-1472
22. Beck SE, Jung BH, Fiorino A, et al. Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 2006;291:G135-45.
23. Wu WK, Sung JJ, Wu YC, et al. Bone morphogenetic protein signalling is required for the antimitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br J Pharmacol 2008;154:632-638